MALVERN, Pa., Feb. 9, 2012 /PRNewswire/ -- Auxilium
Pharmaceuticals, Inc. (NASDAQ: AUXL), a specialty biopharmaceutical
company, will release results for the fourth quarter 2011 on
Thursday, February 23, 2012 before
the opening of the U.S. financial markets. The Company will also
conduct a conference call that day at 10:00
a.m. ET to discuss results and highlights of the fourth
quarter 2011. The presentation slides to be used during the
call will be available on the "For Investors" section of the
Company's web site under the "Presentations" tab beginning at
10 a.m. ET on Thursday, February 23, 2012. A web cast of
the conference call and the presentation slides will be available
on the "For Investors" section of the Company's web site under the
"Events" tab beginning at 10:00 a.m.
ET on Thursday, February 23,
2012. A question and answer session will follow the
presentation.
(Logo: http://photos.prnewswire.com/prnh/20101202/MM10881LOGO
)
Mr. Adrian Adams, Chief Executive
Officer and President, will host the conference call.
Conference
call details:
|
|
Date:
|
Thursday,
February 23, 2012
|
Time:
|
10:00 a.m.
ET
|
Dial-in
(U.S.):
|
866-356-4281
|
Dial-in
(International):
|
617-597-5395
|
Web
cast:
|
http://www.auxilium.com
|
Passcode:
|
AUXILIUM
|
To access
an audio replay of the call:
|
|
Access
number (U.S.):
|
888-286-8010
|
Access
number (International):
|
617-801-6888
|
Replay
Passcode #:
|
50696959
|
About Auxilium
Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical
company with a focus on developing and marketing products to
predominantly specialist audiences, such as urologists,
endocrinologists, certain targeted primary care physicians, hand
surgeons, subsets of orthopedic, general, and plastic surgeons who
focus on the hand, and rheumatologists. Auxilium markets XIAFLEX®
(collagenase clostridium histolyticum) for the treatment of adult
Dupuytren's contracture patients with a palpable cord and Testim®
1%, a testosterone gel, for the topical treatment of hypogonadism
in the U.S. Pfizer has marketing rights for XIAPEX® (the EU
tradename for collagenase clostridium histolyticum) in Europe and Asahi Kasei Pharma Corporation has
development and commercial rights for XIAFLEX in Japan. Ferring International Center S.A.
markets Testim in the EU and Paladin Labs Inc. markets Testim in
Canada. Auxilium has three
projects in clinical development. XIAFLEX is in phase III of
development for the treatment of Peyronie's disease, in phase IIa
of development for the treatment of Frozen Shoulder syndrome
(Adhesive Capsulitis) and is in phase Ib of development for the
treatment of cellulite (edematous fibrosclerotic panniculopathy).
Auxilium also has rights to pursue additional indications for
XIAFLEX. For additional information, visit
http://www.auxilium.com.
AUXILIUM SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES
LITIGATION REFORM ACT OF 1995
This release contains "forward-looking-statements" within the
meaning of The Private Securities Litigation Reform Act of 1995,
including statements regarding the Company's intention to announce
the fourth quarter 2011 results; and products in development for
Peyronie's disease, Frozen Shoulder syndrome and
cellulite.
Forward-looking statements often address Auxilium's expected
future financial position or business strategy and plans and
objectives of management for future operations. Forward-looking
statements provide Auxilium's current expectations or forecasts of
future events. Auxilium's performance and financial results could
differ materially from those reflected in these forward-looking
statements due to various risks and uncertainties.
A more detailed list and description of the risks and
uncertainties that Auxilium faces may be found under the heading
"Risk Factors" in Auxilium's Annual Report on Form 10-K for the
year ended December 31, 2010 and Form
10-Q for the quarter ended September 30,
2011, which are on file with the Securities and Exchange
Commission. Given these risks and uncertainties, any or all of the
forward-looking statements contained in this release may prove to
be incorrect. Therefore, you should not rely on any such factors or
forward-looking statements. Auxilium undertakes no obligation to
update publicly any forward-looking
statement.
Contacts:
James E. Fickenscher/CFO
Auxilium Pharmaceuticals, Inc.
(484) 321-5900
jfickenscher@auxilium.com
William Q. Sargent Jr./ VP IR
Auxilium Pharmaceuticals, Inc.
(484) 321-5900
wsargent@auxilium.com
SOURCE Auxilium Pharmaceuticals, Inc.